Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 14/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL224773 | 1.00 | SIRT2 (0.36) | SIRT2CYP11B1CYP11B2ENPP2FLT3 | |
| SCHEMBL2741599 | 1.00 | SIRT2 (0.36) | SIRT2CYP11B1CYP11B2ENPP2FLT3 | |
| SCHEMBL223715 | 0.81 | CYP11B1 (0.36) | SIRT2CYP11B1CYP11B2ENPP2 | |
| SCHEMBL2741592 | 0.81 | CYP11B1 (0.36) | SIRT2CYP11B1CYP11B2ENPP2 | |
| SCHEMBL223714 | 0.81 | CYP11B1 (0.36) | SIRT2CYP11B1CYP11B2ENPP2 | |
| SCHEMBL224814 | 0.79 | CYP11B1 (0.35) | SIRT2CYP11B1CYP11B2ENPP2 | |
| SCHEMBL224813 | 0.79 | CYP11B1 (0.35) | SIRT2CYP11B1CYP11B2ENPP2 | |
| SCHEMBL2741583 | 0.79 | CYP11B1 (0.35) | SIRT2CYP11B1CYP11B2ENPP2 | |
| SCHEMBL7621404 | 0.77 | CYP11B1 (0.40) | SIRT2CYP11B1CYP11B2ENPP2CYP19A1 | |
| SCHEMBL7796077 | 0.76 | AKR1C3 (0.42) | SIRT2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399463-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO | 2010-08-12 | — | — | US | disclosed |
| EP-2094668-A2 | 4-IMIDAZOLINES AS TAAR'S LIGANDS | F. Hoffmann-Roche AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008074679-A2 | 4-IMIDAZOLINES AS TAAR'S LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146523-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | SIRT2 3927/4885CYP11B1 540/4885CYP11B2 522/4885 |
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | SIRT2 3927/4885CYP11B1 540/4885CYP11B2 522/4885 |
| US-20080146523-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | SIRT2 3927/4885CYP11B1 540/4885CYP11B2 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.